See the DrugPatentWatch profile for Blenrep
What is Blenrep (blenrep eu) used for in the EU?
Blenrep (belantamab mafodotin) is an EU-approved treatment for certain adults with multiple myeloma. It is used in patients who have previously received multiple lines of therapy, including an anti-CD38–based regimen and a proteasome inhibitor and an immunomodulatory drug, and it is typically considered for later-line disease after those prior treatments. [1]
Which countries/versions does “Blenrep EU” refer to?
“Blenrep EU” usually refers to the European Medicines Agency (EMA) authorization and the marketed product status and prescribing information used across EU/EEA markets (for example, the EU SmPC and patient guidance that differ from approvals in the UK or the US). The EU-approved indications and safety warnings are tied to the EMA-authorized label. [1]
What are the main safety issues patients ask about in the EU label?
A key concern with belantamab mafodotin is eye toxicity, including keratopathy/corneal changes and blurred vision, which can require dose delays, dose reductions, or treatment interruption based on severity and monitoring. EU prescribing includes eye assessments and clear steps for managing ocular side effects. [1]
How is it given (and how often) in the EU?
In the EU, Blenrep is administered by healthcare professionals as an intravenous infusion on a defined schedule, with dosing adjustments depending on response and side effects (including ocular findings). The exact dose schedule is described in the EU SmPC. [1]
Is it the same as the US product or the UK product?
The molecule is the same (belantamab mafodotin), but the approved indication wording, dosing, and safety/monitoring language can differ between the EU (EMA label) and other regions (US FDA label, UK MHRA label). Checking the latest EU SmPC is the best way to confirm what applies in the EU. [1]
Where to find the official EU information quickly
You can confirm current EU indication, dosing, and risk-management guidance in the EMA product information (SmPC and patient information). [1]
---
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep